PTC Therapeutics, Inc. Deferred Income Tax Liabilities, Net
PTC Therapeutics, Inc. (PTCT) had Deferred Income Tax Liabilities, Net of $55.91 million as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2025-02-27
- 2024-09-30: Deferred Income Tax Liabilities, Net $55.91M.
- 2024-06-30: Deferred Income Tax Liabilities, Net $55.91M.
- 2024-03-31: Deferred Income Tax Liabilities, Net $55.90M.
- 2023-12-31: Deferred Income Tax Liabilities, Net $55.91M.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2024-09-30 | $55.91M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $55.91M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $55.90M 10-Q · filed 2024-04-25 |
| 2023-12-31 | $55.91M 10-K · filed 2025-02-27 |
| 2023-09-30 | $51.93M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $51.93M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $102.83M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $102.83M 10-K · filed 2024-02-29 |
| 2022-09-30 | $137.11M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $137.11M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $137.11M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $137.11M 10-K · filed 2023-02-21 |
| 2021-09-30 | $136.73M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $136.74M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $136.74M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $136.74M 10-K · filed 2022-02-22 |
| 2020-09-30 | $130.86M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $130.86M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $130.86M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $130.86M 10-K · filed 2021-02-25 |
| 2018-12-31 | $122.03M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |